Despite the evidence indicating that decision aids (DA) improve informed treatment decision making for prostate cancer (PCa), physicians do not routinely recommend DAs to their patients. We conducted semi-structured interviews with urologists (n ¼ 11), radiation oncologists (n ¼ 12) and primary care physicians (n ¼ 10) about their methods of educating low-risk PCa patients regarding the treatment decision, their concerns about recommending DAs, and the essential content and format considerations that need to be addressed. Physicians stressed the need for providing comprehensive patient education before the treatment decision is made and expressed concern about the current unevaluated information available on the Internet. They made recommendations for a DA that is brief, applicable to diverse populations, and that fully discloses all treatment options (including active surveillance) and their potential side effects. Echoing previous studies showing that low-risk PCa patients are making rapid and potentially uninformed treatment decisions, these results highlight the importance of providing patient education early in the decision-making process. This need may be fulfilled by a treatment DA, should physicians systematically recommend DAs to their patients. Physicians' recommendations for the inclusion of particular content and presentation methods will be important for designing a high quality DA that will be used in clinical practice.
Introduction
In 2016, an estimated 180 890 men will be diagnosed with prostate cancer (PCa) in the United States [1] . It is further estimated that 40% of prostate cancers are overdiagnosed [2] , meaning that if the cancers were left undetected, they would not cause a clinical problem for patients. This raises concerns about overtreatment, particularly among patients who are considered to be at low-risk for disease progression, typically defined as having a serum prostate-specific antigen (PSA) of less than 10 and a Gleason score of 6 or less. Due to the slow progression of low-risk disease, active treatments (AT) may place patients at needless risk for side effects such as urinary, bowel and sexual dysfunction when there is little or no clinical benefit. An alternative is to undergo active surveillance (AS), a monitoring protocol that includes serial prostate biopsies and PSA measurements and defers AT until signs of disease progression emerge. Mortality rates are similar for men with low-and very low-risk disease on AS compared to AT for up to 10 years post-diagnosis [3, 4] . Further, AS is now recommended by the National Comprehensive Cancer Network (NCCN) and the American Urological Association (AUA) as a viable treatment alternative for appropriately selected patients [5, 6] . Most physicians believe that AS is a useful and effective management strategy [7, 8] . However, although the rates of AS have increased in recent years, a majority of low-risk PCa patients still choose to receive AT [9, 10] .
A potential barrier to the use of AS in low-risk PCa is that patients may lack sufficient knowledge to make an informed treatment decision [11, 12] . In 2012, Xu et al. reported that most patients recently diagnosed with localized PCa were unaware of the risks of AT. They also had little knowledge of AS and few recalled ever having AS presented to them as a viable treatment option [13] . In a recent study of physicians' treatment discussions with localized PCa patients, physicians only presented a limited set of treatment options and omitted AS altogether in over one-third of the discussions [14] . Likewise, low-risk patients express a need for more accessible information about treatment options and the associated side effects [15, 16] . This information gap suggests that the current decision-making process is not fulfilling patients' specific needs.
One way physicians can help patients to bridge this information gap is by recommending a treatment decision aid (DA) [17] . Although some studies evaluating the efficacy of DAs for newly diagnosed localized PCa have yielded mixed results [18] , several DAs have improved patients' understanding of their treatment options and knowledge of their disease [19] , decreased decisional regret [18, 20, 21] , and improved communication of treatment preferences with their physician [22] . Physicians themselves also report that DAs are useful and have a positive influence on the decision-making process [23, 24] .
Despite the evidence in support of DAs, physicians rarely recommend them to their patients, and as a result, patients rarely use them [24] [25] [26] [27] . In a recent study, only 35% of urologists and radiation oncologists reported using DAs in their practice [24] . Physicians who did not use them believed that their own ability to estimate risk was superior to that of a DA [24] . Physicians also had concerns about the risk of patients misinterpreting information presented in a DA [24] . This concern could be addressed with a DA that facilitates shared decisionmaking between the patient and physician, which few DAs for localized PCa have done [18] .
In order to design a DA that physicians will choose to recommend to their patients, their preferences regarding the format and content of DAs must be addressed [28, 29] . It is important to garner physician support of a DA, as the role of the physician is crucial to its clinical implementation [30] . Further, little is known about how mode and setting of the delivery of DAs, as well as barriers to this delivery, will impact their actual use and effectiveness [31] . The physician's perspective will be useful to identifying how these factors, as well as actual content of the DA, can strengthen their utility.
Therefore, the goal of our study was to identify, through interviews with physicians: (1) the informational needs of low-risk PCa patients and their families during the treatment decision-making process and (2) the essential aspects of a treatment DA that will increase the likelihood that physicians will recommend it to their low-risk patients.
Materials and methods

Participants and recruitment
Eligible participants included urologists, radiation oncologists, and primary care physicians (PCPs) with PCa patients in their practices. Physicians were recruited from academic medical centers, the VA, and private practices in the Washington, DC metro area (N ¼ 17) and from Kaiser Permanente Northern California (KPNC; N ¼ 16). In the DCmetro area, 27 physicians were contacted by email and 17 participated. At KPNC, email announcements about the study were sent to urologists, radiation oncologists and PCPs at two treatment facilities. Sixteen physicians responded to the email announcements and agreed to participate. Of the 33 total physicians, 12 were radiation oncologists, 11 were urologists and 10 were PCPs. Physician demographics are reported in Table I .
Informational needs of low-risk prostate cancer patients Our data collected from KPNC suggests that the low-risk patient population is predominantly white and married, with some college education [32] . Physicians recruited from the DC-metro area, who practice in both university and community-based settings, are likely treat a more diverse patient population, given the demographics of this region.
Procedures
Following IRB approval at KPNC and Georgetown University Medical Center (GUMC), two authors (KD and KT) conducted in-person, semi-structured interviews from October 2014 until March 2015. Physicians signed consent forms allowing the researchers to audio-record the interviews and they received a $50 gift card for their participation. All interviews were transcribed verbatim and coded using the qualitative analysis software program, NVivo 10 [33] .
Interviews
We developed a semi-structured interview guide regarding the treatment decision-making process for low-risk PCa based on our experience with this patient population [34] . Three urologists and one medical oncologist who treat men with PCa reviewed the initial interview guide and modifications were made based on their feedback. The final interview guide included both qualitative and quantitative questions.
Qualitative questions assessed: (1) physicians' methods for educating patients on the natural history of low-risk PCa and on all of the disease management options for low-risk PCa, (2) physicians' reservations or concerns about recommending existing information resources to their patients and (3) physicians' recommendations for specific features of a DA that will increase the likelihood of its use in routine clinical practice.
Nineteen quantitative items assessed the importance of several DA characteristics that may be important in whether physicians recommend them to their patients. Response options ranged from 1 (not at all important) to 4 (extremely important). The DA characteristics included: medium/format (e.g., web or print-based); length; endorsement from professional organizations; frequency of updates; and method of evaluation.
Qualitative data analysis
Three independent coders (CH, PB, KD) used an iterative process to identify recurring themes. Coders independently developed an initial list of themes based on three interviews, came to consensus on the themes, and then independently coded the remaining interviews using NVivo. Coders met periodically to come to consensus on coding discrepancies and to update the list of themes. The final list of topics, themes and exemplar quotes is included in Table II .
Quantitative data analysis
We compared participant responses across the physician specialties and across sites, but due to the small sample sizes, no significance testing was conducted. The list of quantitative questions is presented in Table III .
Results
Physician characteristics are summarized in Table I , stratified by site and specialty. There appeared to be a trend that physicians in the DC-metro area were more often affiliated with an academic institution and not surprisingly, that PCPs tended to see fewer PCa patients than radiation oncologists or urologists.
Qualitative results
Exemplar quotes from each of the themes described below are presented in Table II . We have also highlighted a few quotes in the text below.
Physicians' methods of patient education
Physicians discussed their methods for educating men about the treatment options for low-risk PCa. Many physicians reported the importance of encouraging their patients to take their time to make a decision, accomplished by educating patients on the indolent nature of their disease and Informational needs of low-risk prostate cancer patients "They don't understand the disease, so I calm them down . . .
. I talk to them about the biology of the disease and that this is a different entity, and it's slow progressing, and we have great data to support that . . .
months makes no differ-
ence whatsoever, in intervening, and that's well published." -Urologist, KPNC, 016
We try to stress to them the low-risk nature of their disease, that it's not aggressive, and I hope we do a pretty decent job of calming them.
-Radiation Oncologist, KPNC, 025
Educate patients on all treatment options before making a treatment decision "I don't know you didn't talk to me about it." Those tend to be the people who are upset. I think if you rush somebody into a treatment decision there is more likelihood that they'll be upset." --Radiation Oncologist, DC, 004 
5)
"It has to be easy to use, and I don't think it can be print because they won't read through the whole thing, it's not engaging enough. I think interactive, like web based or on the iPad based, something like that, that we can give in the waiting room or while they're waiting for us would be very, very helpful." -Urologist, DC, 003
(continued) emphasizing the lack of urgency to make a rapid treatment decision.
"I think once they understand that PCa is very slow growing, they feel less pressure to make a rushed decision." -Urologist, DC, 010
Several physicians also reported that patient education may improve long-term treatment satisfaction. Four physicians mentioned that it was important for patients to be educated on all treatment options and outcomes before they made a decision.
"I think the men who took an active treatment choice end up with a lot of side effects and are unhappy and feel that they weren't really given a true option of active surveillance.
And people who choose active surveillance, and the disease progresses, they question whether somebody did something wrong or sneaky, or withheld treatment from them." -Primary Care Physician, DC, 008
Likewise, four physicians believed that patient expectations of treatment outcomes, such as side effects and survival benefits, affect their long-term satisfaction with their treatment choice.
"I think patients should be better informed with regard to side effects for specific treatments. And included in that, patients should not be misled to believe that certain treatments are without side effects because when those occur, the disappointment is greater . . . " -Urologist, DC, 033
Physician concerns about recommending existing educational resources
We assessed physicians' concerns about recommending existing treatment-related educational resources to their patients. While most physicians stated that they had no particular concerns, five physicians reported concerns that their patients could misinterpret information.
"Anytime a patient is receiving or interpreting medical information on their own, there is a Three physicians also expressed their concern that certain informational resources, particularly Internet sources, are not accurate or contain information that has not been properly validated.
"Well, I tell patients, because oftentimes patients go to the internet, so I'll say to them . . . the general advice about finding information on the web is that there's good information and there's bad information." -Primary Care Physician, DC, 008
Recommendations for new DAs
Physicians discussed the particular characteristics that they would like to see in a DA tailored for men with low-risk PCa. Many mentioned that they would prefer a DA that is designed for men with low literacy and applicable to diverse populations.
"We give very verbose booklets and websites, most people don't have the time, patience, or reading level to really get anything out of it." -Radiation Oncologist, KPNC, 020 Eight physicians specifically mentioned that a DA should be interactive and web-based. Two physicians also suggested that a DA include patient video testimonials.
Regarding the information that a DA should include, 11 physicians stressed that it should cover all standard treatment options and outcomes. Ten mentioned the need to include information about potential treatment side effects. One physician also suggested that a DA include information on how to treat or manage these side effects.
"I guess transparency about the side effects of the treatments. I think patients get very confused, and they hear a lot of different things about the incidence of this or that, and I think that for a decision tool in medicine . . . that's critical to be able to have something like that.
-Radiation Oncologist, DC, 006
Fourteen physicians said that a DA should include risk information that helps patients weigh treatment side effects, disease progression, and survival. Specifically, many of these physicians suggested using a nomogram.
"And to kind of see where you are and what the trajectory of prostate cancer mortality vs. overall mortality, if there was a little tool to do that I think that would be really cool. Someone could just see in the same screen this is my risk of death per year for everything, and this is how much is contributed by my diagnosis of early stage prostate cancer, which is almost a flat line compared to my risk of heart disease. They'll say "and I'm spending all this time worrying about this contribution?" I think they would go, "ohhh." But it's kind of hard to put that on a white board, you know what I mean? Cause everybody is a little bit different. So a nomogram thing would really be kind of cool." -Radiation Oncologist, DC, 004
Five physicians (three PCPs) indicated that DAs should be linked to the patients' electronic medical records (EMR).
"I use electronic medical records every single day and so linking those tools to diagnoses within existing electronic medical records . . . would be powerful. We have not done very well with that."
Two physicians believed that a DA should also include information targeted to family and spouses.
Quantitative results: DA characteristics (Table III) Medium/format of DAs Across all specialties, most physicians indicated that it was 'very important' or 'extremely important' for a DA to be available in web format (78.8%). The same number of physicians also endorsed the importance of availability in print format. DVDs and mobile app formats were less commonly endorsed. Unlike radiation oncologists, a majority of urologists (60.0%) and PCPs (70.0%) responded that it was very or extremely important to embed the DA into the electronic medical record (EMR) to provide a cue to physicians to use it.
Timing of DA utilization
Almost all physicians (84.8%) indicated that it was important for a DA to be designed for use after a consultation, when the patient is at home. PCPs (70.0%) and radiation oncologists (54.6%) were more likely than urologists (20.0%) to say that a DA should be designed for the patient and physician to review together during a consultation. Among all physicians, 36.4% believed that it was very or extremely important that a DA be designed for use both during and after a consultation.
Decision aid length
While all radiation oncologists and PCPs indicated that it was important for the DA to be less than 
Frequency of review of content
Most urologists (70.0%) and radiation oncologists (81.8%) believed annual reviews of the content were 'very important' or 'extremely important.' However, most PCPs (70.0%) said that DAs could be updated every 2 years.
Professional organization
Physicians tended to favor a DA that was endorsed by their particular specialty's organization. For example, 70.0% of urologists believed it was important for a DA to be endorsed by the American Urology Association (AUA), 45.5% of radiation oncologists preferred a DA to be endorsed by the American Society for Radiation Oncology (ASTRO) and 50.0% of PCPs said that the DA should be endorsed by the American Academy of Family Physicians (AAFP).
Method of DA evaluation
Physicians were asked about the need for the impact of a DA to be evaluated by randomized trials and/or observational studies. A majority of all physicians (72.7%) said that a DA's efficacy in assisting men with treatment decisions (e.g., decisional conflict, knowledge) should be tested in a randomized controlled trial. Most urologists (80.0%) said that observational data was acceptable for evaluating the efficacy of a DA.
Discussion
In this study, we examined physicians' perspectives on the informational needs of low-risk PCa patients and their families through an in-person semi-structured interview. Physicians highlighted the importance of patient education and described the characteristics of a low-risk PCa DA that would increase the likelihood of its use in clinical practice. To our knowledge, this is one of the only studies to assess physician perspectives on what is needed to improve patient education for men making treatment decisions for low-risk PCa. Given the physician's role in assisting men in understanding all of their treatment options, including active surveillance, this information is central to improving both men's knowledge and their outcomes. Previous studies have reported a low level of patient awareness of the potential risks associated with active treatments and the potential benefits of active surveillance [13, 35, 36] . The physicians in the current study discussed the importance of addressing this information gap. Physicians indicated that patients should be encouraged to take their time in making a treatment decision, as men's comprehension of the low-risk nature of their disease and the lack of urgency to make a treatment choice is important. A well-informed patient who understands the natural history of low-risk PCa may feel less pressure to make a rapid treatment decision, and therefore will be more likely to consider all available treatment options, including AS [37] . Education which focuses on anxiety reduction may be especially important, given the evidence that physicians rarely address patients' emotional distress during treatment consultations [38] . Further, lower anxiety about active surveillance has been associated with remaining on an AS protocol rather than unnecessarily switching to an active treatment in the absence of treatment progression [39] .
In addition to preventing rapid and uninformed treatment decisions, several physicians also stated that patient education can result in better longterm treatment satisfaction. Specifically, physicians reported that a frank discussion about treatment side effects helps to prevent patients from having unrealistic expectations about their post-treatment functioning.
Most physicians reported having no concerns about recommending existing educational resources to their patients. However, some physicians expressed concerns that patients may misinterpret information on their own. They also indicated that many existing resources are not validated, particularly those on the Internet. These concerns are important, considering the data showing that the Internet is a primary information source for PCa patients making treatment decisions [16, 32] .
The need for patient education and the concerns about unevaluated information resources suggest that a validated DA tailored to low-risk PCa patients may be helpful. The majority of existing PCa DAs has been geared towards patients with localized disease [17] . Some of these DAs do not discuss active surveillance specifically, as this management strategy is less applicable to intermediate-risk, localized PCa [17] . Further, low-risk patients may have an even greater need for a DA, given the need to consider active surveillance in their decision-making process. Studies testing the efficacy of DAs for localized PCa patients have yielded mixed results in their ability to improve men's knowledge and satisfaction with their treatment decision [18] . The effectiveness of future DAs may be improved through the incorporation of physicians' perspectives regarding the information and the format that will be most useful to men with low-risk PCa.
PCPs and urologists were more likely to prefer a DA that was incorporated into the EMR, reflecting previous data that shows high rates of EMR use among these two specialties [40] . Several physicians stressed the need for a concise DA, recommending a brief (i.e., less than 30 min) tool with low literacy requirements. Many physicians also mentioned the need for increased cultural sensitivity and availability in multiple languages. Creating a DA that is simple yet universally applicable for diverse populations will be essential to its wide implementation across many clinical settings.
Consistent with physicians' desire for a DA with reliable information, most preferred that the efficacy of a DA be tested in a randomized controlled trial. Furthermore, regular updates were considered important for its continued use. Many physicians also believed a DA should be designed for use either during or after the consultation. A DA that physicians and patients can use together may improve shared decision-making, which is a feature that is often lacking among existing DAs [18] . Previous studies indicate that physicians are receptive to integrating shared decision-making in their practice [34, 41, 42] . Additionally, using the DA during or after a consultation may mitigate the risk of men misinterpreting information included in educational resources, a concern raised by physicians in the current study. Given that physicians are the primary source of treatment information for their patients [16] and that the physician recommendation is the most important factor in determining if a DA will be used [30] , addressing these concerns is essential to facilitate utilization.
Study limitations include the relatively small sample size, making it difficult to generalize the results beyond the current sample. However, the use of multiple sites and specialties improve the data's generalizability to the overall population of physicians who treat low-risk PCa. Further, due to the richness of our qualitative data from this sample, we believe that the overall themes provide important considerations for future DA development.
The results of our study suggest that a decision tool that is specifically targeted to men with low-risk PCa would receive support from both physicians and their patients. Physicians confirmed the need for a DA for this population by relaying their experiences with their own patients in the treatment decision-making process. However, in order for a DA to improve this process, it must be both effective and well-received.
In order to maximize a DA's effectiveness, decision tools should attempt to incorporate the physician recommendations presented here on content and mode of delivery. These data may also be useful for physicians to include in their treatment discussions with low-risk patients.
Perhaps even more important, this study indicates specific characteristics of a DA that may increase the likelihood that physicians will incorporate it into their clinical practice. Because physicians are largely responsible for the implementation of DAs, their support is crucial to their routine use [30] . Regardless of its efficacy for patients, a DA that does not reach its targeted population will be unable to have an impact on treatment decisions.
Given the controversial nature of low-risk PCa treatment and the evidence suggesting that many patients are making poor treatment decisions, DAs that are both effective and widely used may be critical to addressing the issue of overtreatment and treatment dissatisfaction in this patient population. The current study will be a valuable guide for future research on DA development and implementation. Our research team plans to use these results to create a DA that addresses the unique challenges that lowrisk patients face, a critical component missing from current decision support tools. This will be an important first step to improving treatment decisions, and therefore the quality of life, of men with lowrisk PCa. 
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